Medicines & Healthcare products Regulatory Agency

MHRA

Public Assessment Report

National Procedure

Chlorphenamine Maleate 2 mg/5 ml Oral Solution

(chlorphenamine maleate)

PL 20416/0610

Crescent Pharma Limited

LAY SUMMARY

Chlorphenamine Maleate 2 mg/5 ml Oral Solution (chlorphenamine maleate)

This is a summary of the Public Assessment Report (PAR) for Chlorphenamine Maleate 2 mg/5 ml Oral Solution. It explains how this product was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use this product.

This product will be referred to as Chlorphenamine Maleate Oral Solution in this lay summary for ease of reading.

For practical information about using Chlorphenamine Maleate Oral Solution, patients should read the Patient Information Leaflet (PIL) or contact their doctor or pharmacist.

What is Chlorphenamine maleate Oral Solution and what is it used for?
This application is the same as Allerief 2 mg/5ml Oral Solution (PL 20416/0519), which is already authorised.

The Company responsible for Allerief 2 mg/5 ml Oral Solution has agreed that its scientific data can be used as the basis for the grant of an identical licence for Chlorphenamine Maleate Oral Solution.

Chlorphenamine Maleate Oral Solution is used to treat the allergic symptoms of hay fever and other allergies. It can be used to treat the itchiness, redness, swelling, tenderness and irritation caused by:
- hay fever and other allergies e.g. pet, house dust mites and mould spore allergies
- nettle rash and hives
- skin allergies and dermatitis
- prickly heat and heat rash
- reactions to food, food additives or medicines
- insect bites and stings
- the itchy rash of chicken pox.

How does Chlorphenamine Maleate Oral Solution work?
The active substance, chlorphenamine maleate, is an antihistamine which can help to relieve the symptoms of some allergies and itchy skin rashes.

How is Chlorphenamine Maleate Oral Solution used?
The pharmaceutical form of this medicine is oral solution and the route of administration is oral (taken by mouth).

The patient should follow the directions on the label about when and how to take their medicine.

The patient should always use the spoon provided to take this medicine.

The recommended doses are:

Age	Recommended Dose
Children below 1 year:	Not recommended.
Children aged 1-2 years:	2.5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. **Maximum daily dose: 5ml (2mg) in any 24 hours.**
Children aged 2-6 years:	2.5ml (1mg) every 4 to 6 hours. **Maximum daily dose: 15ml (6mg) in any 24 hours.**
Children aged 6-12 years:	5ml (2mg) every 4 to 6 hours. **Maximum daily dose: 30ml (12mg) in any 24 hours.**
Adults and children 12 years and over	10ml (4mg) every 4 to 6 hours. **Maximum daily dose: 60ml (24mg) in any 24 hours.**

Elderly: The patient should talk to their doctor or pharmacist before they take this medicine as they be more likely to get side effects including confusion and they may need to take a lower dose.

For further information on how Chlorphenamine Maleate Oral Solution is used, refer to the PIL and Summary of Product Characteristics (SmPC) available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

This medicine can be obtained without a prescription.

The patient should always take the medicine exactly described in the PIL or as their doctor/pharmacist has told them. The patient should check with their doctor or pharmacist if they are not sure.

What benefits of Chlorphenamine maleate Oral Solution have been shown in studies?
Chlorphenamine Maleate Oral Solution is considered identical to the previously authorised product with the same benefits and risks. No new studies have been provided for Chlorphenamine maleate oral solution, however, reference is made to the studies for Allerief 2 mg/5 ml Oral Solution.

What are the possible side effects of Chlorphenamine Maleate Oral Solution?
For the full list of all side effects reported with this medicine, see Section 4 of the PIL or the SmPC available on the MHRA website.

If a patient gets any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the product information or the PIL that comes with the medicine. Patients can also report suspected side effects themselves, or a report can be made on behalf of someone else they care for, directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' online. By reporting side effects, patients can help provide more information on the safety of this medicine.

Chlorphenamine Maleate Oral Solution is considered to be identical to the previously authorised product with the same benefits and risks.

Why was Chlorphenamine Maleate Oral Solution approved?
The MHRA decided that the benefits of Chlorphenamine Maleate Oral Solution are greater than the risks and recommended that this medicine is approved for use.

What measures are being taken to ensure the safe and effective use of Chlorphenamine Maleate Oral Solution?
A Risk Management Plan (RMP) has been developed to ensure that Chlorphenamine Maleate Oral Solution is used as safely as possible. Based on this plan, safety information has been included in the SmPC and the PIL, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored and reviewed continuously.

Other information about Chlorphenamine Maleate Oral Solution
A Marketing Authorisation was granted in the United Kingdom (UK) on 20 August 2021.

The full PAR for Chlorphenamine Maleate Oral Solution follows this summary.

This summary was last updated in October 2021.

TABLE OF CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) considered that the application Chlorphenamine Maleate 2 mg/5 ml Oral Solution (PL 20416/0610) could be approved.

Chlorphenamine Oral Solution is indicated for the symptomatic control of all allergic conditions responsive to antihistamines including hay fever, allergic rhinitis, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites. It is also indicated for the symptomatic relief of itch associated with chickenpox.

Chlorphenamine (as chlorphenamine maleate) is a potent antihistamine (H_1-antagonist). Antihistamines diminish or abolish the actions of histamine in the body by competitive reversible blockade of histamine H_1-receptor sites on tissues. Chlorphenamine also has anticholinergic activity. Antihistamines act to prevent the release of histamine, prostaglandins and leukotrienes and have been shown to prevent the migration of inflammatory mediators. The actions of chlorphenamine include inhibition of histamine on smooth muscle, capillary permeability and hence reduction of oedema and wheal in hypersensitivity reactions such as allergy and anaphylaxis.

This is a national abridged application approved under Regulation 56 of The Human Medicines Regulations 2012, as amended (previously Article 10c of Directive 2001/83/EC, as amended) as an informed consent application. The application cross-refers to the reference product Allerief 2 mg/5 ml Oral Solution (PL 20416/0519), currently held by Crescent Pharma Limited, which was originally granted in the UK to the Marketing Authorisation Holder, Orbis Consumer Products Ltd, on 23 July 2002, PL 17862/0002.

No new non-clinical or clinical data have been supplied and none are required for this informed consent application.

Suitable justification has been provided for non-submission of an Environmental Risk Assessment (ERA). As the application is an identical version of an already authorised product, no increase in environmental exposure is anticipated and no ERA is required.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product at all sites responsible for the manufacture, assembly and batch release of this product.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with this application and are satisfactory.

A national Marketing Authorisation was granted in the United Kingdom (UK) on 20 August 2021.

II. EXPERT REPORT

The applicant cross-refers to the data for Allerief 2 mg/5 ml Oral Solution (PL 20416/0519; Crescent Pharma Limited), to which this application is claimed to be identical. This is acceptable.

III. ASSESSOR'S COMMENTS ON THE PRODUCT INFORMATION SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

The SmPC is in line with that for Allerief 2 mg/5 ml Oral Solution (PL 20416/0519).

PATIENT INFORMATION LEAFLET (PIL)
A leaflet mock-up has been provided which has been aligned with that for Allerief 2 mg/5 ml Oral Solution (PL 20416/0519). The user test report submitted for PL 17496/0025 has been provided.

LABEL
Label mock-ups have been provided.

IV. QUALITY ASPECTS

IV.1 Drug Substance

Drug substance specification
The source of the active substance is in line with the cross-reference product. The proposed drug substance specification is consistent with the details registered for the cross-reference product.

IV.2. Drug Product

Name
The product has been named in line with current requirements.

Strength, pharmaceutical form, route of administration, container and pack sizes
Chlorphenamine Maleate 2 mg/5 ml Oral Solution is available in amber Type III glass bottles, each with a child resistant, tamper-evident polypropylene cap. The product is supplied with a 2.5/5 ml-measuring spoon. The product is available in pack sizes of 100 ml and 150 ml.

The appearance of the product is identical to that of the cross-reference product.

The proposed shelf life of the product is 2 years with the recommended storage condition ‘Do not store above 25ºC. Store in the original container.’

The proposed packaging, shelf life and storage conditions are consistent with the details registered for the reference product.

Legal status
Pharmacy (P) medicine.

Manufacturers
The proposed manufacturing sites are consistent with the details registered for the cross-reference product and evidence of GMP compliance has been provided.

Qualitative and quantitative compositions
The composition of the proposed product is consistent with the details registered for the cross-reference product.

Manufacturing process & control of critical steps
The proposed manufacturing processes and process controls are consistent with the details registered for the reference product and the maximum batch size is stated.

Finished product release/shelf life specifications
The finished product specifications at release and shelf-life are in line with the details registered for the cross-reference product.

TSE Compliance
No excipients of animal or human origin are used in the final product.

This product does not contain or consist of genetically modified organisms (GMO).

NON-CLINICAL ASPECTS
As this application is submitted under Regulation 56 of The Human Medicines Regulations 2012, as amended, (as an informed consent application) no new non-clinical data have been supplied and none are required.

V. CLINICAL ASPECTS
As this application is submitted under Regulation 56 of The Human Medicines Regulations 2012, as amended, (as an informed consent application) no new clinical data have been supplied and none are required.

VI. RISK MANAGEMENT PLAN (RMP)
The applicant has submitted an RMP, in accordance with the requirements of Regulation 182 of The Human Medicines Regulations 2012, as amended. The applicant proposes only routine pharmacovigilance and routine risk minimisation measures for all safety concerns. This is acceptable.

VII. USER CONSULTATION
A full colour mock-up of the PIL has been provided with the application, in accordance with legal requirements.

The PIL has been evaluated via a user consultation with target patient groups, in accordance with legal requirements, on the basis of a bridging report making reference to Chlorphenamine 2 mg/5 ml oral solution (PL 17496/0025; Dalkeith Laboratories). The bridging report submitted by the applicant is acceptable.

VIII. OVERALL CONCLUSION, BENEFIT/RISK AND RECOMMENDATION
The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The applicant's product is identical to the cross-reference product. The benefit/risk balance is, therefore, considered to be the same as for the cross-reference product and positive.

The SmPC, PIL and labelling are satisfactory, in line with current guidelines and consistent with the cross-reference product.

In accordance with legal requirements, the current approved UK version of the SmPC and PIL for this product are available on the MHRA website.

Representative copies of the labels at the time of licensing are provided below.


Chlorphenamine Maleate
Oral Solution
2mg/5ml
150ml
Hayfever and allergy relief for adults and children over 1 year.
Fast relief from:
• Hayfever symptoms of the eyes and nose
• Heat rash and prickly heat
• Hives and nettle rash
• Insect bites or stings
• Itchy rash of chickenpox
• Skin allergies and dermatitis
• Dust mite, mould spores and pet allergies
• Allergic reactions to food, food additives and medicines.
Keep out of the sight and reach of children.
Do not store above 25°C.
Store in the original container.
Warning: This medicine may make you feel sleepy. If this happens do not drive or use tools or machines. Do not drink alcohol whilst taking this medicine.
PL holder: Crescent Pharma Ltd, 3 & 4 Quidhampton Business Units, Overton, Hampshire, RG25 3ED, UK
P PL 20416/0610
5 017123 332982
C1016B
Chlorphenamine Maleate
Oral Solution
Each 5ml contains 2mg of chlorphenamine maleate as an active substance.
Strawberry Flavour
2mg/5ml
It also contains: sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217) and maltitol. See enclosed leaflet for full list of ingredients.
150ml
Crescent
Directions:
Read the package leaflet before use.
Oral use.
Use the enclosed spoon to measure the dose.
Age | How much to give
Children below 1 year: | Not recommended.
Children aged 1-2 years: | 2.5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose: 5ml (2mg) in any 24 hours.
Children aged 2-6 years: | 2.5ml (1mg) every 4 to 6 hours. Maximum daily dose: 15ml (6mg) in any 24 hours.
Children aged 6-12 years: | 5ml (2mg) every 4 to 6 hours. Maximum daily dose: 30ml (12mg) in any 24 hours.
Adults and children 12 years and over: | 10ml (4mg) every 4 to 6 hours. Maximum daily dose: 60ml (24mg) in any 24 hours.
Elderly: Talk to your doctor or pharmacist before you take this medicine as you may be more likely to get side effects including confusion and you may need to take a lower dose.
• Do not take more medicine than the label tells you to.
• If symptoms persist consult your doctor.
Chlorphenamine Maleate
Oral Solution
Each 5ml contains 2mg of chlorphenamine maleate as an active substance.
Strawberry Flavour
2mg/5ml
It also contains: sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217) and maltitol. See enclosed leaflet for full list of ingredients.
150ml
Crescent
BN:
EXP:


Chlorphenamine Maleate
Oral Solution
Each 5ml contains 2mg of chlorphenamine maleate as an active substance.
2mg/5ml
150ml
Crescent
Hayfever and allergy relief for adults and children over 1 year. It also contains: sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217) and maltitol. See enclosed leaflet for full list of ingredients. Read the package leaflet before use. Oral use. Use the enclosed spoon to measure the dose. Keep out of the sight and reach of children. Do not store above 25°C. Store in the original container. Warning: This medicine may make you feel sleepy. If this happens do not drive or use tools or machines. Do not drink alcohol. PL holder: Crescent Pharma Ltd, 3 & 4 Quidhampton Business Units, Overton, Hampshire, RG25 3ED, UK.
Age | How much to give
Children below 1 year: | Not recommended.
Children aged 1-2 years: | 2,5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose: 5ml (2mg) in any 24 hours.
Children aged 2-6 years: | 2.5ml (1mg) every 4 to 6 hours. Maximum daily dose: 15ml (6mg) in any 24 hours.
Children aged 6-12 years: | 5ml (2mg) every 4 to 6 hours. Maximum daily dose: 30ml (12mg) in any 24 hours.
Adults and children 12 years and over: | 10ml (4mg) every 4 to 6 hours. Maximum daily dose: 60ml (24mg) in any 24 hours.
Elderly: Talk to your doctor or pharmacist before you take this medicine as you may be more likely to get side effects including confusion and you may need to take a lower dose.
P
PL 20416/0610
L0359
Unvarnished area for BN and EXP date.

escent

TABLE OF CONTENTS OF THE PAR UPDATE

Steps taken after the initial procedure with an influence on the Public Assessment Report (non-safety variations of clinical significance).

Please note that only non-safety variations of clinical significance are recorded below and in the annexes to this PAR. The assessment of safety variations where significant changes are made are recorded on the MHRA website or European Medicines Agency (EMA) website. Minor changes to the marketing authorisation are recorded in the current SmPC and/or PIL available on the MHRA website.

Application type	**Scope**	**Product information affected**	**Date of grant**	**Outcome**	**Assessment report attached Y/N**